Xuanjing Bio Secures Over RMB 100 Million in Series Angel+ Financing to Advance siRNA Drug Pipeline and Extrahepatic Delivery Platforms
Rigerna
Innovative Small Nucleic Acid Drug Developer
This article is reprinted from the WeChat Official Account: Cell and Gene Therapy Field
On October 21, 2024, Rigerna announced the completion of an angel+ round of financing exceeding RMB 100 million. This round was co-led by Shanghai Science Investment Co., Ltd. and Qihang Investment, with follow-on investments from Xincheng Fund, JSG United Runpu, Yuanxi Haihe, and others. Existing shareholder Sanyi Innovation Investment also increased its investment. The proceeds from this round will primarily be used for the clinical research of the company’s first siRNA drug, RG002C0106, the advancement of multiple preclinical pipelines, and the rapid development of non-liver tissue in vivo delivery technology and corresponding pipelines.
Rigerna was founded in 2022 and led by Dr. Huang Yuanyu, who has over 16 years of expertise in the nucleic acid pharmaceutical field. Dr. Huang previously worked for many years at a leading small nucleic acid pharmaceutical company, where he led the establishment of several small nucleic acid pharmaceutical technology platforms, advanced the development of various pipelines, and successfully brought them to clinical stages. He is one of the earliest pioneers globally in nucleic acid drug research and one of the trailblazers in China’s small nucleic acid pharmaceuticals sector. Dr. Huang has been recognized as a National-level Young Talent, a top 2% global scientist for five consecutive years, a Beijing Science and Technology Nova, a Gusu Leading Talent, a Suzhou Industrial Park Leading Talent, and a "New Gateway" Leading Talent of Daxing District, Beijing. He has also served as a special guest on CCTV's "Innovation Road" program. Dr. Huang has published over 120 papers in prestigious journals such as Nat Rev Bioeng, Sci Adv, Nat Commun, STTT, and Adv Mater, and filed more than 40 patents, including over 10 PCT patents. Shortly after its founding, Rigerna quickly gained the favor and support of professional pharmaceutical investment institutions with long-term interests in the small nucleic acid space, namely Sanyi Innovation Investment and Haizhi Capital.
Under the leadership of Dr. Huang Yuanyu, Rigerna has rapidly assembled a team with over 10 years of industry experience, possessing extensive expertise and deep understanding in the research and development of small nucleic acid drugs. Their professional backgrounds and work experiences cover the entire process of small nucleic acid drug development. At the same time, Rigerna has quickly established a small nucleic acid drug development platform with global independent intellectual property rights — featuring design and screening technology RIHOST®, chemical modification technology RICMO®, and in vivo delivery technology LICOD®. Based on this, the company is efficiently advancing the development of innovative drug candidates targeting intrahepatic and extrahepatic indications with global rights. To date, a series of key milestone achievements have been made, including: (i) establishing the second-generation GalNAc conjugate delivery technology globally; (ii) preclinical studies of its leading pipeline RG002C0106 have demonstrated excellent efficacy and safety, with clinical trials approved in both China and Australia. Clinical enrollment has already commenced, and it has the potential to become the world’s first-in-class small nucleic acid drug; (iii) developing multiple non-liver tissue delivery technologies based on several exclusive strategies, among which the renal tissue delivery technology is the first and only one globally to complete non-human primate trial validation, achieving an inhibition efficiency of over 70%.
E.N.D
Article Recommendation(Click the article title below to open the original text)：
The CSRC Takes Action, Investigation Initiated!
Rigerna Completes Pre-A Round Financing
Rigerna Goes Bankrupt, Zhang Lei Returns to China, and a New Cycle Begins for Pharmaceutical Venture Capital!
Hengrui Medicine Subsidiary’s AAV Dual-Gene Drug Approved for Clinical Trials in China
Hengrui Medicine Subsidiary’s AAV Dual-Gene Drug Approved for Clinical Trials in China
Rigerna Therapeutics Completes Over 100 Million Yuan in Series B Financing
First In Vivo CAR-T Therapy Clinical Results Released
For DMD, the listing application of this exosome cell therapy is about to be completed.
Research Progress on mRNA Pulmonary Delivery Systems
China's Biotech Finds New Path to Financing
Comprehensive Layout of Gene Therapy Drug NL003 Commercialization, Neuroland Shanghai Branch Opens
mRNA-LNP In Vivo Gene Editing Therapy Advances to Phase 3 Clinical Trials
WuXi AppTec Responds to Rumors of Selling Cell and Gene Therapy Business, Citing Uncertainty
2024 Nobel Prize in Physics Announced
Statement:The content is sourced from the company's official channels. This article aims to share knowledge, and all content is for reference only, not constituting any advice.